TMDX (TransMedics Group) Change In Working Capital : $-45.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Change In Working Capital?

TransMedics Group's change in working capital for the quarter that ended in Dec. 2024 was $-5.8 Mil.

TransMedics Group's change in working capital for the fiscal year that ended in Dec. 2024 was $-45.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

TransMedics Group Change In Working Capital Historical Data

The historical data trend for TransMedics Group's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Change In Working Capital Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-5.59

3.00

-26.76

-44.35

-45.00

TransMedics Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Working Capital	Get a 7-Day Free Trial															-5.56	-28.10	0.18	-11.25	-5.83

TransMedics Group Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

TransMedics Group Change In Working Capital Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Executives

Tamer I Khayal	officer: Chief Commercial Officer	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Edward M Basile	director	200 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein	director, officer: President & CEO	TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Nicholas Corcoran	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Anil P. Ranganath	officer: See Remarks	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephen Gordon	officer: Chief Financial Officer	200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill	director	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Miriam Provost	officer: VP of US Regulatory & FDA Rel.	2000 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey	officer: VP of Operations	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme	officer: VP, Clinical Affairs	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr	director
Rakesh P. Godhani	officer: Chief Digital Officer	C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan	officer: VP of Quality & Engineering	200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810